Amanda Pacheco

Cooley advised Puhe BioPharma, a biotechnology company dedicated to the research and development of innovative small-molecule precision therapeutics, on its global license agreement with Bayer for Puhe BioPharma’s oral, small-molecule protein arginine methyltransferase 5 inhibitor that selectively targets metabolic enzyme 5’-deoxy-5’-methylthioadenosine phosphorylase-deleted tumors.

Cooley advised VISEN Pharmaceuticals, a late-stage, near-commercialization biopharmaceutical company focused on providing treatments for select endocrine diseases in Greater China (including Hong Kong, Macau and Taiwan), on its HK$783 million (approximately US$101 million) initial public offering (IPO) on the Stock Exchange of Hong Kong, subject to the exercise of a 15% overallotment option.

Cooley advised Hummingbird Bioscience, a Singapore-based biotherapeutics company working at the interface of artificial intelligence and human innovation to discover and develop transformative medicines for hard-to-treat diseases, on its exclusive worldwide license agreement with Callio Therapeutics, a newly launched biotech company focused on realizing the promise of multipayload antibody-drug conjugates (ADCs) to improve cancer therapy.

Cooley advised Avenzo Therapeutics, a clinical-stage biotechnology company developing next-generation oncology therapies, on its exclusive license agreement with Duality Biotherapeutics (DualityBio), pursuant to which Avenzo will develop, manufacture and commercialize AVZO-1418/DB-1418– a potential best-in-class epidermal growth factor receptor (EGFR)/human epidermal growth factor receptor 3 (HER3) bispecific antibody-drug conjugate (ADC) – globally (excluding Greater China). 

Cooley advised H1, a global healthcare data technology company, on its acquisition of Ribbon Health.